Literature DB >> 17180679

ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma.

Yasuo Takamune1, Tetsuro Ikebe, Osamu Nagano, Hideki Nakayama, Kazutoshi Ota, Takehisa Obayashi, Hideyuki Saya, Masanori Shinohara.   

Abstract

ADAM-17 (a disintegrin and metalloproteinase 17) is a membrane-anchored protein, which can cleave the ectodomain in a variety of transmembrane proteins. In the in vitro experiments with tumor cells, ADAM-17 is reported to cleave CD44, an adhesion molecule that interacts with hyaluronic acid, to promote tumor cell migration. In the present study, we examined ADAM-17 expression and CD44 cleavage in specimens from 50 patients diagnosed to have oral squamous cell carcinoma (SCC). Each specimen was divided into two pieces, one was studied by immunohistochemistry and the other was subjected to a Western blot. By coordinating the results of both analyses, ADAM-17 expression was evaluated to be high in 23 cases (46%). When CD44 cleavage was also studied by immunohistochemical staining as well as with Western blotting, CD44 cleavage was judged to be positive in 29 cases (58%). When the ADAM-17 expression level was compared with the CD44 cleavage state, most of the cases expressing high levels of ADAM-17 (87%) showed positive CD44 cleavage. The level of ADAM-17 expression was significantly correlated to the nodal metastasis and local recurrence in oral SCC. Our findings suggest that ADAM-17 is involved in CD44 cleavage and contributes to tumor progression in oral SCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17180679     DOI: 10.1007/s00428-006-0350-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

1.  Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer.

Authors:  S M Sheen-Chen; W J Chen; H L Eng; C C Sheen; F F Chou; Y F Cheng
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

2.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.

Authors:  M L Moss; S L Jin; M E Milla; D M Bickett; W Burkhart; H L Carter; W J Chen; W C Clay; J R Didsbury; D Hassler; C R Hoffman; T A Kost; M H Lambert; M A Leesnitzer; P McCauley; G McGeehan; J Mitchell; M Moyer; G Pahel; W Rocque; L K Overton; F Schoenen; T Seaton; J L Su; J D Becherer
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

3.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Authors:  R A Black; C T Rauch; C J Kozlosky; J J Peschon; J L Slack; M F Wolfson; B J Castner; K L Stocking; P Reddy; S Srinivasan; N Nelson; N Boiani; K A Schooley; M Gerhart; R Davis; J N Fitzner; R S Johnson; R J Paxton; C J March; D P Cerretti
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

4.  Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.

Authors:  Frédérique Blanchot-Jossic; Anne Jarry; Damien Masson; Kalyane Bach-Ngohou; Jacques Paineau; Marc G Denis; Christian L Laboisse; Jean-François Mosnier
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

5.  Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: A correlation with histological grade, pattern of stromal invasion, and cell differentiation.

Authors:  I Fonseca; T Pereira; J Rosa-Santos; J Soares
Journal:  J Surg Oncol       Date:  2001-02       Impact factor: 3.454

6.  Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.

Authors:  Stéphanie Fabre-Lafay; Sarah Garrido-Urbani; Nicolas Reymond; Anthony Gonçalves; Patrice Dubreuil; Marc Lopez
Journal:  J Biol Chem       Date:  2005-03-22       Impact factor: 5.157

7.  TACE is required for the activation of the EGFR by TGF-alpha in tumors.

Authors:  Maria Borrell-Pagès; Federico Rojo; Joan Albanell; Josep Baselga; Joaquín Arribas
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

8.  Expression of CD44 is repressed in neuroblastoma cells.

Authors:  E Shtivelman; J M Bishop
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

9.  Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer.

Authors:  Y J Guo; G Liu; X Wang; D Jin; M Wu; J Ma; M S Sy
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

10.  Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration.

Authors:  M Kajita; Y Itoh; T Chiba; H Mori; A Okada; H Kinoh; M Seiki
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  13 in total

Review 1.  Roles of extracellular nucleotides and P2 receptors in ectodomain shedding.

Authors:  Aleta Pupovac; Ronald Sluyter
Journal:  Cell Mol Life Sci       Date:  2016-05-14       Impact factor: 9.261

2.  Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Authors:  Xiqiang Liu; Antonia Kolokythas; Jianguang Wang; Hongzhang Huang; Xiaofeng Zhou
Journal:  Curr Cancer Ther Rev       Date:  2010-11-01

3.  In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages.

Authors:  Tatiana Smirnova; Alfred Adomako; Joseph Locker; Nico Van Rooijen; Michael B Prystowsky; Jeffrey E Segall
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

4.  Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study.

Authors:  Daniele Minardi; Guendalina Lucarini; Alessandra Filosa; Antonio Zizzi; Oriana Simonetti; Anna Maria Offidani; Gianluca d'Anzeo; Roberto Di Primio; Rodolfo Montironi; Giovanni Muzzonigro
Journal:  Cell Oncol (Dordr)       Date:  2012-09-13       Impact factor: 6.730

5.  ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients.

Authors:  Kai Wu; Mingmei Liao; Bo Liu; Zhansheng Deng
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

6.  Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.

Authors:  Lisheng Ge; Dejan Baskic; Per Basse; Lazar Vujanovic; Sebnem Unlu; Toshie Yoneyama; Andrea Vujanovic; Jie Han; Dragic Bankovic; Miroslaw J Szczepanski; Jennifer L Hunt; Ronald B Herberman; Susanne M Gollin; Robert L Ferris; Theresa L Whiteside; Eugene N Myers; Nikola L Vujanovic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

Review 7.  ADAM function in embryogenesis.

Authors:  Dominique Alfandari; Catherine McCusker; Hélène Cousin
Journal:  Semin Cell Dev Biol       Date:  2008-09-30       Impact factor: 7.727

8.  Invasive behavior of ulcerative colitis-associated carcinoma is related to reduced expression of CD44 extracellular domain: comparison with sporadic colon carcinoma.

Authors:  Tetuo Mikami; Tsutomu Yoshida; Yoshiko Numata; Masaomi Kikuchi; Kayo Araki; Norihiro Nakada; Isao Okayasu
Journal:  Diagn Pathol       Date:  2011-04-07       Impact factor: 2.644

9.  Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression.

Authors:  J-W Kornfeld; S Meder; M Wohlberg; R E Friedrich; T Rau; L Riethdorf; T Löning; K Pantel; S Riethdorf
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

Review 10.  Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis.

Authors:  Jianqiang Chen; Jianding Zhou; Jie Lu; Hua Xiong; Xueli Shi; Liang Gong
Journal:  BMC Cancer       Date:  2014-01-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.